Survey highlights 'crucial' safety issues in rhinitis treatment, particularly in children

June 28, 2001

Children may be at risk of receiving rhinitis treatment that suppresses growth - but the problem can be avoided through careful selection of treatment. This was the overwhelming message emerging from a recent nationwide survey of ENT specialists.

According to the findings, the vast majority (91%) of specialists surveyed said they considered growth suppression the most important potential adverse drug reaction associated with nasal steroids. And a similar proportion (88%) said the selection of a nasal steroid for a child should be based on its low potential for adverse effects on growth.

The use of systemic steroids has been linked to growth suppression but the danger is not necessarily avoided by using topical preparations because beclomethasone dipropionate [1] and budesonide[2] nasal sprays have both been associated with growth inhibition in children. By contrast, mometasone furoate (Nasonex) has evidence[3] to suggest that it may not suppress growth in children.

Commenting on the survey, Dr Chris Corrigan, Honorary Consultant Physician and Clinical Senior Lecturer in the Academic Department of Respiratory Medicine & Allergy at Guy's, King's and St Thomas's School of Medicine pointed out that adverse drug reactions surrounding the use of steroids were emotive issues, "Nevertheless, it seems sensible to use a preparation that couples maximum efficacy with minimal systemic bioavailability, particularly in patients who are receiving additional topical corticosteroids for other diseases, such as asthma or eczema."

In the telephone survey, two out of three specialists (67%) said that, when selecting a nasal steroid for the management of allergic rhinitis, they rated a combination of high efficacy and low systemic bioavailability as very important (9 or more on a scale of 1-10). Indeed, guidelines for the management of rhinitis[4] recommend using topical once-daily nasal steroids with low bioavailability - namely mometasone furoate or fluticasone propionate.

Of the available treatments for rhinitis, the survey respondents rated mometasone furoate over any other treatment as one with an appropriate balance of efficacy and safety for the treatment of allergic rhinitis. When asked to rate the appropriateness of available treatments for rhinitis, 39% of ENT specialists rated mometasone furoate as being very appropriate (9 or more on a scale of 1-10), while 26% rated fluticasone propionate as very appropriate.

The corresponding figures for triamcinolone acetonide, betamethasone sodium phosphate and beclomethasone dipropionate were 20%, 12% and 2% respectively. Other available preparations were rated by less than 10% of respondents as very appropriate. Dr Corrigan reviewed the survey results and noted, "It is probably appropriate that mometasone furoate was at the top of this list, since this preparation is of particularly high potency and particularly low systemic bioavailability."

The safety of treatments for rhinitis should be a key consideration when managing patients, according to the results of the survey. Dr Samantha Walker, Head of Allergy & Research at the National Asthma & Respiratory Training Centre added that the balance of safety and efficacy is also important - taking a 'safe' treatment is not very useful if it fails to control symptoms.

The treatment of allergic rhinitis - now the most common chronic disease in man - is increasingly an issue for GPs. Since the 1950s the number of consultations GPs see for rhinitis has quadrupled. According to Dr Walker, the prevalence of allergic rhinitis is "rising and is now higher than it has ever been." Nevertheless, there are effective modern treatments capable of controlling symptoms in most people.

According to the guidelines for the management of rhinitis, topical corticosteroid nasal sprays and the newer non-sedating antihistamines are the mainstays of treatment.
-end-
Notes for editors

This survey was conducted by telephone among 58 Ear, Nose & Throat specialists in the UK in June 2001 by the market research company Martin Hamblin according to the Market Research Society Code of Conduct. If you require a further breakdown of results, or are interested in a feature article, contact Juliet Roberts or Mike Livesey at Phase IV: e-mail: Juliet@phaseiv.co.uk Tel: 020-8288-0444; Fax: 020-8288-0445. Further information follows by post but if you require information immediately, please do not hesitate to contact us.

Note: All nasal steroids have the potential to suppress growth. It is recommended that the height of children on nasal steroids is regularly monitored.

References

1 Skoner DP, Rachelefsky GS, Meltzer EO et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Paediatrics 2000; 105(2): electronic 23.

2 Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993; 82: 635-640.

3 Schenkel EJ, Skoner DP, Bronsky EA et al. Absence of growth retardation in children with perennial allergic rhinitis following 1 year of treatment with mometasone furoate aqueous nasal spray. Paediatrics 2000; 105(2): electronic 22.

4 British Society for Allergy and Clinical Immunology ENT Sub-Committee. Rhinitis Management Guidelines. Third Edition. Martin Dunitz. 2000.

Phase IV Communications

Related Steroids Articles from Brightsurf:

Study shows protective role sex steroids play in COVID-19
''Sex and Covid-19: A protective role for reproductive steroids,'' by Graziano Pinna, research associate professor in psychiatry, analyzes existing research to look at reasons why COVID-19 symptom severity and mortality are more frequent in men than in women and in older people.

New RA guideline emphasizes maximizing methotrexate and biologics, minimizing steroids
The American College of Rheumatology (ACR) will preview its 2020 Guideline for the Management of Rheumatoid Arthritis (RA) at ACR Convergence, the ACR's annual meeting.

Microwaves are useful to combine amino acids with hetero-steroids
Aza-steroids are important class of compounds because of their numerous biological activities.

Early steroids improve outcomes in patients with septic shock
Some critically ill patients with septic shock need medications called vasopressors to correct dangerously low blood pressure.

Cumulative doses of oral steroids linked to increased blood pressure
Cumulative doses of oral steroids in patients with chronic inflammatory diseases are associated with increased hypertension (blood pressure) for those who take them regularly, found new research in CMAJ (Canadian Medical Association Journal).

Fewer steroids, no plasma exchange: A change in treatment for vasculitis
The insights from the PEXIVAS Trial, a 10-year study, shows treatment for ANCA-associated vasculitis can use half the standard dosage of steroids and involve no blood plasma exchanges.

Steroids could do more harm than good in treating coronavirus
Steroids should be avoided in the treatment of the current novel coronavirus, experts have advised.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

One third of patients with severe asthma are taking harmful doses of oral steroids
A third of patients with severe asthma are taking harmful doses of oral steroids, according to a study of several thousand people in The Netherlands, presented at the European Respiratory Society International Congress.

Oral steroids put patients with inflammatory disease at high risk of infection
Oral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses, found a study in CMAJ (Canadian Medical Association Journal).

Read More: Steroids News and Steroids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.